Skip to content

Immunoblot for Antibodies to Myelin Basic Protein (MBP) in Serum

Published: August 9, 2026Updated: August 16, 2026

This test detects antibodies against a protein found in the brain’s myelin sheath, which can help identify certain autoimmune conditions affecting the nervous system.

Quick summary

["Helps diagnose conditions like multiple sclerosis or other demyelinating diseases by checking for immune system responses to brain proteins."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
89511-0
Short code
GM3 IgG+IgM Ser Ql Line blot
Synonyms
GM3 IgG+IgM Ser Ql Line blot
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
line-blot
CPT
82784
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

Myelin Basic Protein (MBP) is a key protein in the protective covering of nerve fibers. If your immune system mistakenly attacks MBP, it may produce antibodies that can be detected in your blood. This test looks for these antibodies, which can signal inflammation or damage in the central nervous system.

Why It Might Be Ordered

Your healthcare provider may recommend this test if you have symptoms like numbness, weakness, vision changes, or other neurological issues that could suggest an autoimmune disease targeting the brain or spinal cord.

Common Conditions Linked to Positive Results

Positive results may indicate conditions such as multiple sclerosis, neuromyelitis optica (devic’s disease), or other inflammatory or demyelinating disorders. However, false positives can occur, so further evaluation is often needed.

What to Expect Before the Test

No special preparation is needed. You’ll provide a blood sample, usually drawn from your arm. The test involves collecting serum (liquid part of blood after clotting).

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: This test is primarily used as a diagnostic aid for autoimmune neurological disorders. Elevated antibody levels can support a clinical suspicion of demyelinating diseases but are not definitive on their own. Results should be interpreted alongside patient symptoms, physical exam findings, and possibly additional imaging or tests.

Short name

MBP Antibody Screening (Serum)

Frequently asked questions

Will this test show if I have multiple sclerosis?
This test can help identify certain autoimmune conditions affecting the nervous system, including multiple sclerosis, but it is not definitive. Other tests and evaluations are often needed for a full diagnosis.
What does a positive result mean?
A positive result suggests the presence of antibodies against MBP, which may indicate an autoimmune response. However, further testing and clinical correlation are required to determine the exact cause of your symptoms.
Can I eat or drink before this test?
No special diet or fasting is required for this blood test. You can eat and drink normally before your appointment.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy